We are live on !
Find out more
PFM Health Sciences Portfolio holdings
AUM
$1.17B
Turnover
44.83%
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter Est. Return
+32.88%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$1.17B
AUM Growth
+$68.7M
(+6.3%)
Cap. Flow
+$9.42M
Cap. Flow % of AUM
Cap. Flow %
0.81%
Top 10 Holdings %
Top 10 Hldgs %
33.9%
Holding
116
New
34
Increased
23
Reduced
41
Closed
18
Avg Time Held
Equity + Options
1.1
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.9
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
1
year
Top 20 Avg Time Held Equity only
1
year
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$26.9M |
| 2 |
Ascendis Pharma A/S
ASND
|
+$19M |
| 3 |
Mettler-Toledo International
MTD
|
+$16.1M |
| 4 |
Merck
MRK
|
+$14.9M |
| 5 |
Cytokinetics
CYTK
|
+$13.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tenet Healthcare
THC
|
+$50M |
| 2 |
Eli Lilly
LLY
|
+$27.1M |
| 3 |
Penumbra
PEN
|
+$25.8M |
| 4 |
Glaukos
GKOS
|
+$23.2M |
| 5 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$21M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.83% |
| 2 | Miscellaneous | 1.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
MBX Biosciences
MBX
$2.78B
| $3.92M | 0.34% |
70,971
-923
| -1% | -$32.2K |
2025 Q3
3 quarters
|
|
77
Mirum Pharmaceuticals
MIRM
$6.14B
| $3.69M | 0.32% |
+31,536
| New | +$3.17M |
2026 Q2
0 quarters
|
|
78
Cullinan Oncology
CGEM
$667M
| $3.5M | 0.3% |
192,442
-34,964
| -15% | -$519K |
2025 Q4
2 quarters
|
|
79
Compass Pathways
CMPS
$1.28B
| $3.5M | 0.3% |
247,589
-1,119,510
| -82% | -$11.4M |
2022 Q2
16 quarters
|
|
80
HCA Healthcare
HCA
$104B
| $3.23M | 0.28% |
8,295
-5,056
| -38% | -$2.14M |
2022 Q3
15 quarters
|
|
81
Capricor Therapeutics
CAPR
$554M
| $2.94M | 0.25% |
122,221
-1,610
| -1% | -$48.8K |
2026 Q1
1 quarter
|
|
82
Denali Therapeutics
DNLI
$3B
| $2.6M | 0.22% |
+100,966
| New | +$2.07M |
2026 Q2
0 quarters
|
|
83
Syndax Pharmaceuticals
SNDX
$851M
| $2.59M | 0.22% |
118,422
-126,599
| -52% | -$2.63M |
2025 Q3
3 quarters
|
|
84
Amylyx Pharmaceuticals
AMLX
$3.89B
| $2.58M | 0.22% |
143,700
-1,575
| -1% | -$24.4K |
2025 Q1
5 quarters
|
|
85
Tarsus Pharmaceuticals
TARS
$3.96B
| $2.55M | 0.22% |
40,579
-39,647
| -49% | -$2.53M |
2025 Q4
2 quarters
|
|
86
Outset Medical
OM
$70.4M
| $2.51M | 0.22% |
582,122
-12,508
| -2% | -$54.7K |
2025 Q1
5 quarters
|
|
87
Omada Health Inc
OMDA
$889M
| $2.51M | 0.22% |
+114,442
| New | +$1.83M |
2026 Q2
0 quarters
|
|
88
Erasca
ERAS
$5.48B
| $2.46M | 0.21% |
+134,088
| New | +$1.92M |
2026 Q2
0 quarters
|
|
89
Cencora
COR
$68.5B
| $2.09M | 0.18% |
+7,385
| New | +$2.13M |
2026 Q2
0 quarters
|
|
90
BioCryst Pharmaceuticals
BCRX
$1.96B
| $2.07M | 0.18% |
+207,357
| New | +$1.88M |
2026 Q2
0 quarters
|
|
91
Omnicell
OMCL
$1.61B
| $2.04M | 0.17% |
+49,040
| New | +$1.98M |
2026 Q2
0 quarters
|
|
92
CVRx
CVRX
$17.3M
| $1.9M | 0.16% |
+369,572
| New | +$2.39M |
2026 Q2
0 quarters
|
|
93
Hims & Hers Health
HIMS
$4.62B
| $1.71M | 0.15% |
+49,454
| New | +$1.33M |
2026 Q2
0 quarters
|
|
94
Mineralys Therapeutics
MLYS
$1.36B
| $1.68M | 0.14% |
62,418
-80,259
| -56% | -$2.2M |
2025 Q4
2 quarters
|
|
95
Tectonic Therapeutic
TECX
$413M
| $1.57M | 0.13% |
45,631
-498
| -1% | -$14.6K |
2025 Q4
2 quarters
|
|
96
uniQure
QURE
$1.67B
| $1.22M | 0.1% |
26,396
-16,239
| -38% | -$425K |
2024 Q1
9 quarters
|
|
97
Rezolute
RZLT
$353M
| $662K | 0.06% |
127,289
-1,437
| -1% | -$5.34K |
2025 Q2
4 quarters
|
|
98
Caribou Biosciences
CRBU
$39.1M
| $624K | 0.05% |
354,687
-603,100
| -63% | -$1.19M |
2021 Q3
19 quarters
|
|
99
Alignment Healthcare
ALHC
$1.54B
| – | – |
-359,826
| Closed | -$6.34M | – |
|
|
100
CALL
Ascendis Pharma A/S
ASND
$18.1B
| – | – |
-22,400
| Closed | -$5.12M | – |
|
Similar funds
PFM Health Sciences's Q2 2026 Portfolio in Review
As of Q2 2026, PFM Health Sciences held 116 positions worth $1.17B, up 6.3% from $1.1B the previous quarter. Its ten largest holdings account for 34% of the portfolio.
PFM Health Sciences's Q2 2026 filing shows 34 new, 23 increased, 41 reduced and 18 closed positions. Its largest new stake was Humana: 94,375 shares worth $37.5M. The largest sale was Tenet Healthcare, an estimated $50M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Miscellaneous.
- PFM Health Sciences's largest Q2 2026 buy was Humana: 94,375 shares worth $37.5M.
- PFM Health Sciences added most to Ascendis Pharma A/S in Q2 2026, an estimated $19M increase.
- PFM Health Sciences's biggest Q2 2026 reduction was Tenet Healthcare, cutting an estimated $50M.
- PFM Health Sciences fully exited Glaukos in Q2 2026, selling an estimated $23.2M.
- PFM Health Sciences's ten largest holdings make up 34% of its $1.17B portfolio in Q2 2026.
- PFM Health Sciences opened 34 new positions and closed 18 in Q2 2026.
- PFM Health Sciences's portfolio value rose 6.3% quarter-over-quarter to $1.17B.
Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.